• June 3-6, 2024
  • San Diego Convention Center, California

Sessions

Loading

Suntec Medical

Thursday, June 06, 2024
Start-Up Stadium Session
Platform for Therapeutics
Company Description: Suntec has a proprietary MINC (Multi-target Immune-modulation Nanocomplex) technology platform to develop highly effective and safe immunotherapies. MINC applies to neurodegenerative diseases such as Alzheimer's, Parkinson's and immunotherapies for cancer, vaccine, and autoimmune diseases. Suntec has a pipeline of 6 drug candidates in pre-clinical development stage with potentials of "breakthrough"designations. STM-001 was awarded with NIH support to treat breast, ovarian, gastric, glioma and brain-metastatic cancers. STM-002 in combination with anti-PD-1/PD-L1 can bring the total efficacy/response to 60% (vs 20% for anti-PD-1/PD-L1 alone). Both candidates will enter human trials in 2024. Suntec has 3 drug candidates for Alzheimer’s (AD) and Parkinson’s (PD) diseases. MINC vehicles carry protein drugs to the brain in high concentrations. Without the MINC platform, these proteins penetrate the brain at 0.001-0.1%. With the MINC platform, they penetrate a wobbly 4-10%. MINC also reduces brain edema caused by these protein drugs and reduces neural cell death and promotes neural cell regeneration to recover cognitive behavior for AD/PD patients.

Suntec Medical
Company Website: http://Suntec Medical

Company HQ City

Walnut

Company HQ State

California

Company HQ Country

United States

CEO/Top Company Official

Pauline Lau
Primary Speaker
Pauline Lau, PhD
Founder
Suntec Medical
Back to Session List

white squarewhite

BIO DOUBLE HELIX SPONSORS

Thanks to our sponsors for supporting our mission to drive a revolution to cure patients, protect our climate, and nourish humanity.

Loading

BIO HELIX SPONSORS